In the Appendix 4E and Annual Report some wording (page 14) seemed to allude to part of the revenue attributable to sales in Australia. "OncoSil had a cash balance of $12.2 million as at 30 June 2021. During the year, OncoSil made modest inaugural revenue from
the sale of the OncoSil™ device of $213k in Australia and New Zealand".
Ann: Appendix 4E and Annual Report, page-23
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.38M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $71.81K | 11.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 10730612 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 9523384 | 12 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |